Clinical trial
Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study
NCT00004183 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2000
- Completion date
- January 31, 2006
- Enrollment
- 27 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.
malignant mesothelioma